Review of Pharmacology - 9E (2015)

Chemotherapy B: Antimicrobials for Specific Conditions
610
Review of Pharmacology
135. Which of the following statements about lamivudine is
false: (RJ 2008)
(a) Possess Anti–HIV and anti-HBV activity
(b) Dose lower for blocking HIV replication than HBV
replication
(c) Should not be used as monotherapy in HBV/HIV
infected patients
(d) Anti-HBe seroconversion occurs in minority of
patients
136. Which of the following is most common side effect of
zidovudine? (MH 2003)
(a) Anemia
(b) Peripheral neuropathy
(c) Lactic acidosis
(d) All
137. A laboratory technician was accidentally exposed to
a HIV serum positive sample, which of the following
shall be the role of zidovudine in treatment of this
patient? (MH 2003)
(a) Protects against acquiring the HIV infection
(b) Makes the patient seronegative
(c) Delays the progression of disease
(d) None
138. Prophylactic therapy should be started against
Pneumocystis carinii pneumonia in AIDS patients with
CD4 counts below: (Karnataka 2003)
(a) < 50/microL (MH 2005)
(b) < 150/microL
(c) < 200/microL
(d) < 400/microL
139. Which of the following anti-HIV drug should never be
given as rechallange once history of producing allergic
reaction with drug is known?
(a) Lamivudine (MH 2006)
(b) Abacavir
(c) Zidovudine
(d) Nelfinavir
140. All are protease inhibitor except: (Bihar 2005)
(a) Ritonavir
(b) Amprenavir
(c) Tenofovir
(d) Nelfinavir
141. Which protease inhibtor has boosting effect?
(a) Amprenavir (Bihar 2005)
(b) Tenovir
(c) Nelfinavir
(d) Ritonavir
142. Which of the following is a protease inhibitor?
(a) Lamivudine (AP 2004)
(b) Saquinavir
(c) Delavirdine
(d) Zidovudine
143. Following drugs act against HIV-2 Except: (MP 2009)
(a) Ritonavir
(b) Tenofovir
(c) Efavirenz
(d) Zalcitabine
144. Enfuvirtide belongs to the class of: (MP 2009)
(a) Fusion inhibitors
(b) Protease inhibitors
(c) Gp 120 inhibitors
(d) Nucleotide reverse transcriptase inhibitors
145. Drug which produces Steven Johnson’s syndrome in
HIV infected individuals is: (MP 2009)
(a) Paraaminosalicylate
(b) Cycloserine
(c) Thioacetazone
(d) Rifampicin
146. In anti retroviral therapy, Zidovudine should not be
combined with: (MP 2009)
(a) Lamivudine
(b) Nevirapine
(c) Didanosine
(d) Stavudine
147. The HIV fusion inhibitor, enfuvirtide, acts at the site
of: (MP 2009)
(a) Gp 120
(b) Gp 41
(c) P24
(d) CXCR4
148. Viral HIV integrase inhibitor is:
(a) Zidovudine (Kolkata 2009)
(b) Maroviroc
(c) Raltegravir
(d) Enfuvirtide
149. All the following antiretroviral drugs produce
dyslipidemia except: (Karnataka 2006)
(a) Atazanavir
(b) Saquinavir
(c) Amprenavir
(d) Nelfinavir
anti-malarial drugs
150. All of the following are criteria for high risk of deveoping
chloroquine retinopathy except:
(a) Duration of use > 5 years (AIIMS Nov. 2011)
(b) Seen at a dose of >250mg/d or >3mg/kg
(c) >480g total dose
(d) Presence of renal failure
151. The development of resistance to conventional treatment
has led WHO to recommend the use of combination
therapies containing artemisinin derivative (artemisinin-based
combination therapies also known as
https://kat.cr/user/Blink99/